Lilly Eyes Aesthetic Medicine as GLP-1 Weight Loss Reshapes Faces
Eli Lilly is exploring aesthetic medicine as GLP-1 patients face facial volume loss and laxity — but no products, trials, or timelines are confirmed yet.
Topic
Glp 1
Topic
Glp 1
Eli Lilly Eyes Aesthetic Medicine as GLP-1 Weight Loss Reshapes Patient Demand
Eli Lilly is exploring aesthetic medicine as GLP-1-driven weight loss creates visible facial and body changes, the Indianapolis B…
Survey Finds More GLP-1 Patients Seeking Cosmetic Dermatology Care
A new Dermatology Times survey report finds rising numbers of GLP-1 patients seeking cosmetic care, driven by facial volume loss…
Aesthetic Medicine Pursues Multi-Billion-Dollar GLP-1 Market
A Yahoo Finance analysis attributes a multi-billion-dollar aesthetic medicine surge to weight-loss drugs. The source omits analys…
GLP-1 combination therapy signals new benefits in psoriasis
GLP-1 combination therapy may bring added benefits to psoriasis patients, The Hill reports, though no trial design, cohort, or PA…
JAAD Examines Dual Financial Interests in Weight-Loss and Aesthetic Care
JAAD's 10 October 2026 ethics analysis by Shaikh, Grant-Kels and colleagues examines conflicts when clinicians profit from weight…
New Study Points to Possible Biological Link Between GLP-1 Drugs and Hair Loss in Men
New research reported October 3, 2026 suggests a possible biological link between GLP-1 drugs like Ozempic and hair thinning in m…
GLP-1 Drugs and Psoriasis: What the Evidence Actually Shows
GLP-1 receptor agonists are drawing attention as potential psoriasis therapy, but the evidence so far is observational and mechan…
GLP-1 Use Linked to Fourfold Higher Rate of Nail Detachment
Nail detachment occurred four times more often in patients on GLP-1 receptor agonists, adding onycholysis to the cutaneous signal…
GLP-1 Drug Makes Its Case for Treating Plaque Psoriasis
A GLP-1 receptor agonist is drawing dermatologic attention as a possible therapy for plaque psoriasis, with MedPage Today surveyi…